TrialSignal
Clinical trial intelligence report
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 18, 2026
NCT ID
NCT04486352
Status
RECRUITING
Phase
PHASE1
Sponsor
Alliance Foundation Trials, LLC.
Executive brief
Investment-Ready Snapshot
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04486352
Indication
Endometrial Cancer
Modality
monoclonal antibody
Target
Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib
Intervention
Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.